Abstract
The ubiquitin-proteasome pathway plays an important role in the regulation of cellular proteins with regard to cell cycle control, transcription, apoptosis, cell adhesion, angiogenesis and tumor growth. Proteasome inhibition is a novel approach to the treatment of solid tumors. Bortezomib is the first proteasome inhibitor evaluated in clinical trials. In vitro experiments have shown that bortezomib treatment has a cytotoxic effect on various breast, colorectal, ovarian, pancreatic, prostate, lung and oral cancer cells. Here, the usefulness of proteasome inhibitor for cancer therapy is discussed, and a review of preclinical and clinical studies on proteasome inhibitors alone and in combination with conventional chemotherapy is included.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Boronic Acids / pharmacology
-
Boronic Acids / therapeutic use*
-
Bortezomib
-
Cell Physiological Phenomena
-
Clinical Trials as Topic
-
Drug Design
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / etiology
-
Neoplasms / pathology
-
Protease Inhibitors / pharmacology
-
Protease Inhibitors / therapeutic use*
-
Proteasome Endopeptidase Complex / physiology*
-
Proteasome Inhibitors*
-
Pyrazines / pharmacology
-
Pyrazines / therapeutic use*
-
Ubiquitin / physiology
Substances
-
Antineoplastic Agents
-
Boronic Acids
-
Protease Inhibitors
-
Proteasome Inhibitors
-
Pyrazines
-
Ubiquitin
-
Bortezomib
-
Proteasome Endopeptidase Complex